H. Valle de Hebron

Barcelona 8035

2 studies enrolling now · 3 studies all time

What they study most

Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), IDH1-mutant Glioma, IDH2-mutant Glioma, Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation, Myelodysplastic Syndromes (MDS)

Studies at this site

• Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation — Recruiting now
• Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation — Recruiting now
• Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma — Running, not enrolling